Drug EfficacyPatients treated with eblasakimab experienced a rapid onset of action and a significant reduction in Eczema Area and Severity Index scores, highlighting its effectiveness in treating atopic dermatitis.
Market OpportunityWith over 60% of patients treated with dupilumab not achieving the desired outcome, eblasakimab presents a substantial market opportunity as an alternative treatment for atopic dermatitis.
Upcoming MilestonesASLAN Pharmaceuticals is set to unveil compelling translational data from a head-to-head study of eblasakimab vs. dupilumab at an imminent scientific congress, potentially bolstering the drug's profile.